Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00185341
Status:
COMPLETED
Last Update Posted:
2016-05-02
First Post:
2005-09-12
Brief Title:
Study to Investigate the Efficacy of a Non-hormonal Drug Against Endometriosis Associated Pelvic Pain
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
A Multicenter Double-blind Randomized Placebo-controlled Parallel-group Study to Evaluate the Safety Tolerability and Efficacy of the CCR1 Antagonist ZK 811752 Given Orally in a Dose of 600 mg Three Times Daily for the Treatment of Endometriosis Over 12 Weeks
Status:
COMPLETED
Status Verified Date:
2016-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study was designed as a proof-of-concept trial to evaluate safety tolerability and the efficacy of 1800 mg ZK 811752 600 mg given orally three times daily over 12 weeks for the treatment of endometriosis associated pelvic pain EAPP in comparison to placebo
Detailed Description:
The study has previously been posted by Schering AG Germany Schering AG Germany has been renamed to Bayer Schering Pharma AG Germany
Bayer Schering Pharma AG Germany is the sponsor of the trial
Bayer Schering Pharma AG Germany is the sponsor of the trial
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2004-000630-37 | EUDRACT_NUMBER | None | None |
| 308601 | EudraCT Number | None | None |